Eli Lilly (LLY) Goodwill & Intangibles (2009 - 2026)
Eli Lilly (LLY) posted Goodwill & Intangibles of $13.5 billion for Q1 2026, up 8.74% quarter-over-quarter from $12.4 billion in Q4 2025, and up 14.61% year-on-year from $11.8 billion in Q1 2025.
Eli Lilly (LLY) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Eli Lilly (LLY) has reported Goodwill & Intangibles for 18 consecutive years, with $13.5 billion the latest figure, recorded in Q1 2026.
- Goodwill & Intangibles for Q1 2026 came in at $13.5 billion, up 14.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.5 billion (up 14.61% YoY), and the FY2025 annual result was $12.4 billion, up 4.05% from the prior year.
- Goodwill & Intangibles was $13.5 billion for Q1 2026 at Eli Lilly, up from $12.4 billion in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $13.5 billion in Q1 2026 and troughed at $10.9 billion in Q3 2023.
- Average Goodwill & Intangibles over 5 years is $11.8 billion, with a median of $11.7 billion recorded in 2024.
- Year-over-year, Goodwill & Intangibles declined 6.42% in 2022 and increased 14.61% in 2026.
- Over 5 years, Goodwill & Intangibles stood at $11.3 billion in 2022, then gained by 5.02% to $11.8 billion in 2023, then gained by 0.76% to $11.9 billion in 2024, then grew by 4.05% to $12.4 billion in 2025, then advanced by 8.74% to $13.5 billion in 2026.
- Per Business Quant data, the three most recent Goodwill & Intangibles figures were $13.5 billion in Q1 2026, $12.4 billion in Q4 2025, and $12.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.50 Bn |
| Dec 31, 2025 | 12.42 Bn |
| Sep 30, 2025 | 12.34 Bn |
| Jun 30, 2025 | 11.68 Bn |
| Mar 31, 2025 | 11.78 Bn |
| Dec 31, 2024 | 11.94 Bn |
| Sep 30, 2024 | 12.31 Bn |
| Jun 30, 2024 | 12.40 Bn |
| Mar 31, 2024 | 11.70 Bn |
| Dec 31, 2023 | 11.85 Bn |
| Sep 30, 2023 | 10.87 Bn |
| Jun 30, 2023 | 10.98 Bn |
| Mar 31, 2023 | 11.16 Bn |
| Dec 31, 2022 | 11.28 Bn |
| Sep 30, 2022 | 11.02 Bn |
| Jun 30, 2022 | 11.39 Bn |
| Mar 31, 2022 | 11.37 Bn |
| Dec 31, 2021 | 11.58 Bn |
| Sep 30, 2021 | 11.77 Bn |
| Jun 30, 2021 | 11.87 Bn |